Clinical trial
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid…
NCT00086983 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00086983 |
|---|---|
| Title | Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors |
| Official title | A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | becatecarin, oxaliplatin, pharmacological study |
| Enrollment | 15 |
| Start date | May 1, 2004 |
| Primary completion | Sep 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Jan 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: